Protagenic Therapeutics Warrant
PTIXW
PTIXW was delisted on the 2nd of January, 2026.
0 hedge funds and large institutions have $0 invested in Protagenic Therapeutics Warrant in 2026 Q1 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, reducing their positions, and 3 closing their positions.
6.39% less ownership
Funds ownership: 6.39% → 0% (-6.4%)
100% less funds holding
Funds holding: 3 → 0 (-3)
100% less capital invested
Capital invested by funds: $5.47K → $0 (-$5.47K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.71K |
| 2 |
CS
Clear Street
New York
|
-$2.39K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$371 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CS
1
Clear Street
New York
| – | -$2.39K | -100,000 | Closed |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$2.71K | -87,596 | Closed |
|
|
TSS
3
Two Sigma Securities
New York
| – | -$371 | -15,533 | Closed |
|
PTIXW Hedge Fund Activity: Q1 2026 in Review
0 of the 8,134 institutional investors tracked by Wall St. Rank reported a position in Protagenic Therapeutics Warrant (PTIXW) for Q1 2026, worth a combined $0 — down 100% from $5.47K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of PTIXW and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Susquehanna International Group, exiting entirely with an estimated $2.71K sold.
- 0 institutional investors held Protagenic Therapeutics Warrant (PTIXW) as of Q1 2026, down from 3 in Q4 2025.
- Funds reported $0 of Protagenic Therapeutics Warrant stock for Q1 2026, down 100% quarter-over-quarter.
- 0 funds opened new Protagenic Therapeutics Warrant positions in Q1 2026 and 3 closed out, a net change of -3 holders.
- The largest Protagenic Therapeutics Warrant seller in Q1 2026 was Susquehanna International Group, an estimated $2.71K sold.
Based on aggregated 13F filings for Q1 2026.